After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

The singer-songwriter, who found fame as a member of the girl group Little Mix on the UK’s “The X Factor,” shared her account about a date she once went on with Styles in a recently ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...

One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat the roughly 5,000 CF patients who can't benefit from Vertex's other CF products. The other is from a phase ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

In a court filing on Monday, the Department of Health and Human Services fired back at Vertex Pharmaceuticals ... regardless whether that patient elects to purchase Vertex’s Product, or its competitor ...